Management of anticoagulation during dermatosurgical procedures in Germany - results from a cross-sectional study

J Dtsch Dermatol Ges. 2013 Jan;11(1):52-9. doi: 10.1111/j.1610-0387.2012.08003.x. Epub 2012 Aug 17.

Abstract

Background: Treatment with antiplatelet drugs (APD) and vitamin K antagonists (VKA) can be a challenge during the management of dermatosurgical interventions.

Methods: We performed a cross-sectional study on the perioperative management of APD and VKA in dermatological private practices and clinics in Germany, using anonymized, standardized questionnaires.

Results: 233 responses were evaluated (response rate 37 %). Skin biopsies are performed in 82.7 % of offices and in 90.8 % of clinics despite treatment with VKA. Small excisions are done in 62.5 % of offices and 76.9 % of clinics during treatment with VKA, for large excision this applies to 11.9 % of offices and 33.8 % of clinics. Low-dose treatment with APD (#100 mg) does not hinder 80.4 % of private practices and 89.2 % of clinics to perform small excisions as well as 36.3 % and 53.8 %, respectively, to perform large excisions. Of private practitioners 67.3 % and 83.1 % of clinic-based dermato-surgeons do not consider high-dose APD a contraindication for small excisions, and 25.0 % and 41.5 %, respectively, for large excisions. Most frequently switching to heparin is performed 6-8 days prior to surgery and switching back 0-2 days after surgery.

Conclusions: Large differences in the perioperative management of anticoagulant therapy during dermatosurgical procedures have been identified. Further studies and guidelines should be developed.

MeSH terms

  • Anticoagulants / therapeutic use*
  • Cross-Sectional Studies
  • Dermatologic Surgical Procedures / statistics & numerical data*
  • Germany / epidemiology
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Postoperative Hemorrhage / epidemiology*
  • Postoperative Hemorrhage / prevention & control*
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Prevalence
  • Risk Assessment
  • Surveys and Questionnaires
  • Treatment Outcome
  • Vitamin K / antagonists & inhibitors*

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Vitamin K